/stocks — the workspaceLOADING
All IDXGSEC filings, by type → · Earnings date & implied move · Search inside filings
INTERPACE BIOSCIENCES, INC. (IDXG) is a surgical & medical instruments & apparatus company. Piotroski F-Score 5/8. Next earnings projected around 2026-11-11 from IDXG's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind IDXG’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
FY ending 2025-12-31 vs 2024-12-31.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from IDXG’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on IDXG plus an auto-SWOT — built from IDXG's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate IDXG using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has IDXG been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No tracked institution reported a position in IDXG in the latest 13F round.
No lawmaker has disclosed a trade in IDXG under the STOCK Act.
Every figure is from IDXG’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.
No open-market Form 4 buys or sells reported for IDXG in the last ~6 months.
Projected from IDXG's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentIDXG files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.